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Abstract Epidermal growth factor receptor (EGFR)
expression has been associated with clinical outcome in
some studies of renal-cell carcinoma (RCC). We inves-
tigated the eﬃcacy and safety of geﬁtinib (IRESSA), an
EGFR tyrosine kinase inhibitor, in RCC patients. This
phase II trial recruited 28 patients with advanced, met-
astatic, or relapsed RCC. Patients received oral geﬁtinib
500 mg/day. Objective responses (ORs) were assessed
every 2 months according to RECIST. Baseline tumor
biopsies were analyzed immunohistochemically for
EGFR expression. At trial closure (March 2003), no
ORs were seen but 14 patients (53.8%) had stable dis-
ease. At extended analysis (August 2004), median time
to progression was 110 days (95% conﬁdence interval
[CI]: 55, 117); median overall survival was 303 days
(95% CI 180, 444). Geﬁtinib was generally well toler-
ated. Skin rash and diarrhea were the most common
drug-related adverse events (AEs) [54 and 39% of
patients, respectively] and the most common drug-re-
lated grade 3/4 AEs (both 11%). The majority of tumor
biopsies (91%) had ‡70% of tumor cells expressing
membrane EGFR. Despite the lack of ORs in this study,
disease control was observed in 53.8% of patients.
Geﬁtinib was generally well tolerated and no unexpected
drug-related AEs were observed.
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Introduction
In 2002, renal-cell carcinoma (RCC) accounted for 4%
of adult malignancies globally, with >200,000 cases
diagnosed and 100,000 deaths reported [7]. For
patients with metastatic or recurrent RCC, treatment
options are limited, prognosis is poor, and median
survival is <1 year [16]. Cytotoxic chemotherapy
regimens are relatively ineﬀective and most chemo-
therapy trials demonstrate no clear survival beneﬁt [9].
While those patients who do respond to chemotherapy
often survive longer, only few patients show tumor
regression (e.g., 5–9% of patients experience objective
responses (ORs) with agents such as vinblastine and
5-ﬂuorouracil [5-FU]).
Various immunologic agents have been evaluated,
including interleukin 2 (IL-2) (2–18 million units
[MU]/m2) and interferon alpha (IFN-a) (3–15 MU/
day) [24]. Both drugs have a similar OR rate (com-
plete response [CR] plus partial response [PR]) of 10–
20% in appropriately selected patients (non-bulky
pulmonary and/or soft tissue metastases with perfor-
mance status 0–1 and no weight loss), with an addi-
tional 20–30% of patients experiencing stable disease
(SD) [2, 10, 19, 24]. However, only patients treated
with IL-2 experience durable (>5 years) CR (5% of
patients); those treated with IFN-a rarely have com-
plete or durable responses [24].
Combining IL-2 and IFN-a can increase eﬃcacy end
points slightly, with OR and SD observed in £ 40% of
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patients [2, 10, 19]. The clinical beneﬁt gained using
immunotherapy may be oﬀset by its toxicity, which can
be substantial; grade 3/4 adverse events (AEs) consist of
fatigue, weight loss, fever, myalgia, hypotension,
depression, and hematologic toxicities (e.g., neutrope-
nia, thrombocytopenia, and anemia) [10, 19].
While combination regimens including chemotherapy
agents (e.g., 5-FU or vinblastine) do not improve OR
and SD, they may improve survival end points [3, 18,
21]. In a more recent outpatient regimen, a signiﬁcant
prolongation in progression-free survival (PFS) was
observed for patients with advanced RCC treated with
IFN-a+IL2+5-FU+cis-retinoic acid (7 months) com-
pared with IFN-a+vinblastine (5 months). However,
there was no improvement in PFS with IFN-a+IL2+5-
FU compared with IFN-a+IL2+5-FU+cis-retinoic
acid (6 months) [3]. Similar trends were also observed
for OS. The percentage of patients who discontinued
treatment due to toxicity was 4% in the IFN-a+IL2+5-
FU arm, 6% in the IFN-a+IL2+5-FU+cis-retinoic
acid arm, and 8% in the IFN-a+vinblastine arm [3].
Clearly there is a need for new, eﬀective, and well-tol-
erated therapies for the management of RCC.
Approximately 70–90% of RCC cases express the
epidermal growth factor receptor (EGFR) [1, 23], which is
known tobe involved in key tumorigenic processes such as
proliferation, invasion, survival, and angiogenesis [12, 14,
25, 27, 29]. EGFR expression has been associated with
clinical outcome in some studies of RCC. For example,
reduced survival and an increased risk of metastatic dis-
ease have been observed in patients whose tumors express
EGFR [14, 25, 29], while less regional lymph node
involvement, venous invasion, and distant metastases
were observed in patients whose tumors did not express
EGFR [29]. These data suggest that EGFR inhibition
may be a valid treatment option in RCC.
Inhibition of EGFR signaling has been shown to be
eﬀective in the non-small-cell lung cancer setting. Phase
II trials showed that 11.8–18.4% of pretreated patients
with locally advanced or metastatic non-small-cell lung
cancer experienced ORs following treatment with
250 mg/day geﬁtinib (IRESSA), the ﬁrst EGFR tyrosine
kinase inhibitor to be approved for the treatment of
cancer [6]. The majority of drug-related AEs were grade
1/2 mild to moderate diarrhea and skin rash, with few
patients experiencing grade 3/4 AEs [6, 11].
In the absence of eﬃcacy data in RCC at the time
that this phase II trial was designed, a dose of 500 mg/
day was used to investigate the eﬃcacy and tolerability
of geﬁtinib in patients with advanced, metastatic, or
relapsed RCC.
Methods
Trial design and patients
This was an open-label, multicenter, non-comparative,
phase II trial. The primary objective was to determine the
OR rate (CRs and PRs) of 500 mg/day geﬁtinib in pa-
tients with advanced, metastatic, or relapsed RCC. Sec-
ondary objectives included estimating the disease control
rate, time to progression (TTP) and OS, and duration of
response, as well as further evaluation of the safety of
geﬁtinib at a dose of 500 mg/day. An exploratory objec-
tive was to investigate any association between baseline
tumor EGFR expression and response to geﬁtinib.
Inclusion criteria consisted of: histologically con-
ﬁrmed, locally advanced, relapsed or metastatic RCC
that was refractory to, or intolerant of, approved ther-
apies; age ‡18 years; World Health Organization per-
formance status 0–2 or Karnofsky score >70%; life
expectancy of >12 weeks; measurable disease according
to the modiﬁed response evaluation criteria in solid tu-
mors (RECIST). Patients with local tumor resection
were eligible only if local relapse or distant progression
had been radiologically documented.
Any of the following was regarded as a criterion for
exclusion: nephrectomy within 4 weeks of the trial
starting; other co-existing malignancies or malignancies
diagnosed within the previous 5 years (with the excep-
tion of basal-cell carcinoma or cervical cancer in situ);
any unresolved chronic toxicity greater than National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
grade 2 from previous anticancer therapy; incomplete
healing from previous oncologic or other surgery;
absolute neutrophil count <1.0·109/L or platelets
<100·109/L, serum bilirubin >1.25·upper limit of
reference range (ULRR); any evidence of severe or
uncontrolled systemic disease; serum creatinine
>160 lmol/L; alanine aminotransferase or aspartate
aminotransferase >2.5·ULRR if no liver metastases
were present or >5·ULRR in the presence of liver
metastases; evidence of brain metastases; chemotherapy
or cytokine therapy in the 4 weeks prior to enrollment;
radiotherapy within 1 week of enrollment, concomitant
use of CYP3A4 inhibitors (e.g., phenytoin, carbamaze-
pine, barbiturates, rifampicin, or St John’s Wort);
pregnancy or breastfeeding (women of childbearing
potential); any psychiatric disorder that might restrict
patient compliance; patients known to be, or at risk of
being, HIV+.
The trial was conducted in accordance with local and
international regulatory and ethical guidelines, and all
patients gave written, informed consent.
Treatment
Patients received oral geﬁtinib 500 mg/day (two 250 mg
tablets) in the morning as a continuous treatment, at
approximately the same time each day. In the event of
toxicity, geﬁtinib treatment could be interrupted for
£ 14 days, with repeated drug interruptions allowed, as
necessary. If toxicity recurred once geﬁtinib therapy
recommenced and dose interruption was not considered
suﬃcient to manage the toxicity, the dose could be
reduced to 250 mg/day.
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Patients could be withdrawn from the study at any
time at the discretion of the investigating physician.
Discontinuation criteria included: withdrawal of in-
formed consent; objective disease progression; patient
lost to follow-up; initiation of additional antineoplastic
therapies; AEs; protocol non-compliance; death.
Assessments
Eﬃcacy
Objective responses (CRs and PRs) were evaluated using
RECIST. X-rays and computed tomography (CT) scans
were carried out within 3 weeks of study entry. Tumors
were assessed by CT scan every 8 weeks during the ﬁrst
6 months of therapy; thereafter, X-rays and CT scans
were carried out every 12 weeks. Duration of response
was to be calculated as the number of days from the date
of ﬁrst documented response to the earlier of death
(from any cause) or progression, and the last on-study
tumor assessment. The disease control rate was deﬁned
as those patients with ORs plus those with SD conﬁrmed
and sustained for ‡4 weeks.
TTP was calculated as the number of days from the
day of ﬁrst treatment to the earlier of death (from any
cause) or progression, and the last on-study tumor
assessment. OS was assessed as the number of days from
the day of ﬁrst treatment to the earlier of death (from
any cause), and the last date of patient contact.
Tolerability
AEs were recorded throughout the study using NCI-
CTC version 2.0 and causality was assigned by the
investigators. Routine hematology, biochemistry, and
physical examinations were carried out within 7 days
before the start of treatment, on days 1, 15, and 29 of
treatment, and every 28 days thereafter. Urinalysis was
performed as necessary.
Tumor EGFR expression
Tumor EGFR expression levels could be determined in
23 patients from tumor biopsies taken within 21 days of
starting geﬁtinib. Immunohistologic evaluation of tumor
EGFR expression was carried out at an AstraZeneca-
designated laboratory using EGFR pharmDx (Dako-
Cytomation).
Statistical analysis
Fleming’s method was used to calculate the number of
patients required, with 27 patients being suﬃcient to give
an 80% probability of rejecting a baseline response rate
of 5% with an exact one-sided signiﬁcance test when the
true response is at the clinically relevant rate of 20%.
The population for all analyses was the intent-to-treat
(ITT) population. The null hypothesis that the OR rate
was 5% was to be tested against the alternative
hypothesis that the response rate was >5%. If there
were 27 patients in the ITT population and ‡4 of these
patients were responders, the null hypothesis was to be
rejected. If the number of patients in the ITT population
diﬀered from 27, the null hypothesis was to be rejected in
favor of the alternative hypothesis if the 90% conﬁdence
interval (CI) did not include 5%.
The summary statistics for continuous variables were
mean, standard deviation, median, quartiles, minimum,
and maximum. Discrete variables were summarized by
count and proportion. OR and disease control rates
were summarized by proportions, together with a 95%
CI (a 90% CI was also calculated for the OR rate).
Durations (TTP, OS, and response) were summarized by
Kaplan–Meier methods.
An exact logistic regression model would calculate
the regression coeﬃcient of logs-odd tumor response
against EGFR expression, together with a 95% CI.
Results
Patient characteristics
Twenty-eight caucasian patients (19 men, 9 women)
were enrolled into this study from March to Septem-
ber 2002. All patients had metastatic disease. The
baseline patient characteristics are shown in Table 1.
As a per-protocol analysis was not performed, proto-
col deviations were not assessed. Twenty-four patients
met all inclusion and exclusion criteria. Only one pa-
tient had a cytologic analysis of tumor tissue. Three
patients failed the exclusion criterion of having serum
creatinine £ 160 lmol/L; however, as the level for all
three was <190 lmol/L they were all included in the
study.
Treatment
All patients received at least one dose of geﬁtinib.
Median time on trial was 64.5 days (range: 8–354), with
the median duration of treatment being 63 days (range:
8–345).
Eﬃcacy
Twenty-six of 28 patients were evaluable for eﬃcacy. Of
the two patients who were not evaluable for eﬃcacy, one
patient died after 42 days of treatment (before the ﬁrst
radiologic assessment) and the other withdrew informed
consent after 13 days due to minor toxicities. Per the
trial protocol, eﬃcacy data were analyzed at trial closure
(March 2003); however, because median survival had
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not been reached at this time, a second analysis was
performed in August 2004.
Although none of the patients in this study experi-
enced an OR, disease was controlled in 14 of the 26
evaluable patients (53.8%; 95% CI: 33.4, 73.4) at their
ﬁrst radiological assessment at 8 weeks.
At trial closure, 16 patients were alive, and 12 had
died (in whom PD was not documented in two patients).
Median TTP was 99 days (95% CI: 55–114) and
6 months after starting treatment, six patients (21.4%;
96% CI: 6.2–36.6%) were alive and progression free. As
16 patients (57.1%) were alive at trial closure, the
median OS could not be estimated.
A more recent eﬃcacy analysis in August 2004
showed that 24 patients had progressed and 22 had died.
Five patients had experienced prolonged SD for ‡1 year
(range: 12–26+months), including one patient with
clear-cell RCC with multiple lung metastases and distant
lymph node involvement who is still receiving geﬁtinib
(duration: 26+months). Two patients with SD withdrew
informed consent after 5.7 and 15 months, respectively;
the former had documented ongoing SD 18.1 months
after discontinuation of geﬁtinib treatment, and the
latter had disease progression 9 months after discon-
tinuation of geﬁtinib therapy. Median TTP was
110 days (95% CI: 55, 117) and median OS was
303 days (95% CI: 180, 444) (Fig. 1a, b).
Tolerability
All 28 patients were evaluable for safety and the majority
of patients (n=26, 93%) experienced AEs. Drug-related
AEs occurred in 25 patients (89%), the most frequent
being grade 1/2 skin rash (54%) and diarrhea (39%)
(Table 2). Few drug-related grade 3/4 AEs occurred, with
the most common being skin rash (11% of patients) and
diarrhea (11%). One of these patients experienced grade 4
diarrhea (leading to dehydration) and grade 4 renal fail-
ure. Another patient experienced grade 3 febrile neutro-
penia (he had not received prior chemotherapy but had
received spinal and pelvic radiotherapy) and grade 4
deterioration in physical health; this patient later died
from a grade 4 cerebrovascular accident that was not
considered to be drug related.
Drug-related AEs led to dose interruptions and
reductions in seven (25%) and six patients (21%),
respectively. Two patients (7%) discontinued treatment
because of AEs; the patient mentioned above with drug-
related grade 4 deterioration in general condition, and
one patient who had drug-related grade 3 skin rash,
which resolved after treatment discontinuation. There
were no drug-related deaths.
EGFR expression and response
Twenty-three tumor biopsies were available for EGFR
analysis, with the majority of samples (91%) having
‡70% of tumor cells expressing membrane staining for
EGFR (highest intensity of 2+ or 3+). As no ORs
were observed, the exploratory analysis could not be
performed. Three out of the ﬁve patients with pro-
longed SD had tumor biopsies available for analysis
(two patients did not provide a biopsy sample); one
patient had strong EGFR expression (95% membrane
staining with 50% +++) and two patients had weak
membrane staining. Information on EGFR expression
for the patient with ongoing SD is not available.
Discussion
This study has shown that the administration of 500 mg/
day geﬁtinib to patients with advanced, metastatic, or
relapsed RCC did not result in ORs. However, disease
control was observed in 53.8% of patients at 8 weeks,
and the median TTP and OS were 3.6 and 10.3 months,
respectively. Treatment with 500 mg/day geﬁtinib was
generally well tolerated and no unexpected drug-related
AEs were observed.
Our results are comparable to other reported phase II
trials of 500 mg/day geﬁtinib in patients with advanced
RCC. In a study by Drucker et al. [5] involving 16
evaluable patients with advanced RCC, there were no
ORs but disease control was seen in nine patients (56%),
three of whom experienced SD for >4 months. Simi-
larly, no ORs were reported in an abstract with pre-
liminary data by Dawson et al. [4] of 21 evaluable
patients with advanced RCC. One patient had a minor
response (27% reduction in tumor size) and eight pa-
tients (38%) had SD. Median PFS and OS were 2.7 and
8.3 months, respectively [4]. This lack of ORs in patients
with metastatic RCC has also been observed in a phase
II trial of the EGFR monoclonal antibody cetuximab
(ABX-EGF) [15], where TTP was not prolonged with
cetuximab compared with historical IFN-a data. How-
ever, a recent report showed that cetuximab induced
major responses in three out of 88 patients with meta-
static RCC and minor responses in two patients [23].
Median PFS was 100 days, which is comparable to our
data, and the authors noted a trend that the severity of
rash may relate to PFS [23].
Overall, these studies suggest that EGFR-targeted
monotherapy results in a minimal OR rate in patients
with advanced or metastatic RCC, even though cor-
relations between EGFR expression and clinical out-
come have been reported [1, 12, 14, 29]. These clinical
ﬁndings for geﬁtinib in the RCC setting are disap-
pointing, considering that preclinical data have shown
that geﬁtinib inhibits the proliferation of RCC cell
lines (SKRC-49) and signiﬁcantly inhibits the growth
of RCC xenografts (SKRC-49) compared with placebo
(P<0.01) [1]. Moreover, the combination of geﬁtinib
and paclitaxel signiﬁcantly increased SKRC-49 cell
apoptosis in vitro and tumor growth in vivo compared
with geﬁtinib alone [26]. While no data are available
as yet, analysis of renal biopsies for EGFR mutations
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(recently observed in patients with non-small-cell lung
cancer who had striking responses to geﬁtinib [13, 20])
may shed light on the minimal OR rate and prolonged
SD observed in patients with RCC receiving EGFR-
targeted therapies.
More recently, several phase II trials have shown
that targeted inhibition of more than one signaling
pathway associated with RCC is eﬀective in patients
with metastatic disease [8, 17, 22]. Twenty-ﬁve out of
65 evaluable patients (38%) responded to BAY 43-
9006, a novel signal transduction inhibitor that targets
the platelet-derived growth factor receptor (PDGFR)
and vascular endothelial growth factor receptor
(VEGFR) pathways [22], and Motzer et al. [17] re-
ported ORs in 15 out of 63 patients (24%) who were
treated with SU11248, which inhibits the PDGFR,
VEGFR, KIT, and FLT-3 signaling pathways. ORs
were also observed in 10 out of 40 evaluable patients
(25%) following blockade of VEGFR and EGFR
using bevacizumab (an anti-VEGF monoclonal anti-
body) and erlotinib (an EGFR tyrosine kinase inhib-
itor) [8]. Blockade of VEGFR alone has also shown
eﬃcacy in metastatic RCC, with a randomized phase
II trial of bevacizumab and placebo in patients with
metastatic RCC showing signiﬁcantly prolonged TTP
in favor of bevacizumab (4.8 vs. 2.5 months) [28].
Whether geﬁtinib in combination with other targeted
therapies or with cytotoxic chemotherapy agents is
active in patients with RCC remains to be determined.
Fig. 1 a Time to progression
and b overall survival in
patients with renal-cell
carcinoma treated with
500 mg/day geﬁtinib
Table 1 Patient characteristics at baseline (n=28)
Median age (range), years 63 (37–75)
Gender, n (%)
Male 19 (68)
Female 9 (32)
World health organization performance status, n (%)
0 12 (43)
1 13 (46)
2 3 (11)
Prior therapy,a n (%)
None 13 (46)
Immunotherapy 6 (21)
Radiotherapy 4 (14)
Chemotherapy 1 (4)
Immunotherapy and chemotherapy 4 (14)
No. metastatic sites,b n (%)
1 2 (7)
2 7 (25)
3 8 (29)
‡4 11 (39)
Sites of metastases,b n (%)
Lung 18 (64)
Lymph nodes 12 (43)
Liver 8 (29)
Mediastinum 7 (25)
Renal 5 (18)
Adrenal 5 (18)
Other 4 (14)
Soft tissue 3 (11)
aPatients may have received >1 type of prior therapy
bPatients may have >1 metastatic site
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Conclusions
In this study, geﬁtinib did not produce any ORs in pa-
tients with locally advanced, relapsed, or metastatic
RCC. However, disease control was observed in 53.8%
of patients and median TTP and OS were 110 and
303 days, respectively. These ﬁndings are consistent with
other monotherapy trials of geﬁtinib and other EGFR
inhibitors. There were no unusual safety concerns, AEs
being comparable to those previously reported. Despite
the lack of ORs in this study, the level of disease control,
along with preclinical and early clinical combination
data, suggests that combination studies that include
inhibition of the EGFR signaling pathways should be
investigated further.
IRESSA is a trademark of the AstraZeneca group of
companies
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